Trials / Completed
CompletedNCT01727869
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN1400 | |
| DRUG | Erlotinib | |
| DRUG | Cetuximab |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-11-16
- Last updated
- 2015-04-06
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01727869. Inclusion in this directory is not an endorsement.